Porcine Reproductive & Respiratory Syndrome (PRRS) around the World – What’s new regarding Global cross‐protection against PRRS - Dr. PH Rathkjen, Boehringer Ingelheim, from the 2016 North American PRRS Symposium, December 3‐4, 2016, Chicago, Illinois, USA.
More presentations at http://www.swinecast.com/2016-north-american-prrs-symposium
Joe Smentek - Recent Legislative and Regulatory Impacts on Minnesota Agriculture
Similar to Dr. PH Rathkjen - Porcine Reproductive & Respiratory Syndrome (PRRS) around the World – What’s new regarding Global cross‐protection against PRRS
HIV Alert- Novel Strategies and Agents for HIV Management.2016hivlifeinfo
Similar to Dr. PH Rathkjen - Porcine Reproductive & Respiratory Syndrome (PRRS) around the World – What’s new regarding Global cross‐protection against PRRS (20)
Biogenic Sulfur Gases as Biosignatures on Temperate Sub-Neptune Waterworlds
Dr. PH Rathkjen - Porcine Reproductive & Respiratory Syndrome (PRRS) around the World – What’s new regarding Global cross‐protection against PRRS
1. PH Rathkjen
Sr. Global Technical manager PRRS
Boehringer Ingelheim Animal Health GmbH
– What’s new regarding Global
cross-protection against PRRS?
PRRS from around the world
2. From 22 years experience
of heterologous protection against
the economically most important disease
across the globe in19 countries
in Asia, Europe and North America
4. The solution is bigger than the bottle
Maximize immunity & Minimize exposure
5. What is
important
to
control
PRRSV?
People
are the most
important Gilts
replacement
procedures
are the most
important
Location
is the
most
important What
about
pig
Flow?
You
also need
a good
Immunity
Do we need
to take
PRRSV diversity
Into
Consideration?
Heterologous
Protection!
No matter the virus.
That is what
You
Need!
6. North America:
PRRSV type II
some type I
Most South
America:
Free
Australia:
Free
Eastern Europe: PRRSV
type I (2,3)
Western Europe:
PRRSV type I (1) some
type II
Asia:
PRRSV type II (HP)
some type I
Our basic understanding of PRRSV global distribution
7. Results: Differences between
vaccinated and challenge control
animals were statistically significant
(P<0.05) in all studies.
Conclusion:
Under the conditions of these
studies, Ingelvac PRRS® MLV
significantly reduced lung lesions
in multiple challenge models which
used genetically diverse
heterologous PRRSV isolates.
Homology
(%)
94%
100%
90%
89%
90%
87%
87%
89%
89%
87%
87%
88%
86%
87%
9. Worldwide documentation
Japanese isolate bs403929 (internal RD data 2012)
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST
AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE
MODEL
USA SDSU-73 2016
USA, 1-7-4- 2016
China HP-PRRS 2013
Korean PRRS isolates 2015
10. Japanese isolate bs403929
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV
ISOLATE IN A RESPIRATORY CHALLENGE MODEL
internal RD data 2012
11. 28 days
Vaccination
Ingelvac
PRRS® MLV
3 WOA
2 X 20
PRRS neg.
Japanese isolate bs403929
EFFICACYOFINGELVACPRRSMLV FORPROTECTIONAGAINSTANASIANPRRSVISOLATEIN A RESPIRATORY
CHALLENGEMODEL
internal RD data 2012
Blood
Weight
Blood
Weight
Blood
Weight
Blood Blood
14 days
Blood
Design Parameters Results Movinggraphs
12. Design Parameters Results Movinggraphs
Fever (6,7 days vs 3,9 days)
Serum viremia
BAL d 42
0
0.2
0.4
0.6
Diluent MLV
0.56 0.54
0.25
0.44
ADWGkg
ADWG by group and study period
Vaccination period
Challenge period
P=0,0040
0
5
10
15
20
Diluent MLV
Percentconsolidation
Treatment group
Percent pneumonia
Average lung lesion
P=0,0045
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012
13. EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012
14. Design Parameters Results Movinggraphs
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012
15.
16. Design Parameters Results Movinggraphs
28 days
28 doa
2 X 22
PRRS neg.
Blood Blood BloodBlood Blood
21 days
BloodBlood Blood
0 7 14 21 42353228
Vaccination
Ingelvac
PRRS® MLV
17. Design Parameters Results Movinggraphs
Survival curve
0
20
40
60
80
100 Challenge
d30
d31
d32
d33
d34
d35
d36
d37
d38
d39
d40
d41
d42
d43
d44
d45
d46
d47
d48
Necropsy
Survivalratein%
V/C Non-V/C Strict controls
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a
18. Design Parameters Results Movinggraphs
Percent PCR positive & body temperature
0
10
20
30
40
50
60
70
80
90
100
38.5
39
39.5
40
40.5
41
41.5
challenge d31 d33 d35 d37 d39 d41 d43 d45 d47 Necropsy
%PCRpositives
Bodytemperaturein°C
V/C group -PCR NV/C group - PCR V/C group - temp NV/C group -temp
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a
19. Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a
20. Design Parameters Results Movinggraphs
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a
21. Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a
22. Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a
23.
24. Design Parameters Results Movinggraphs
Vaccination
Ingelvac
PRRS® MLV 35 days
21 doa
4 X 30
1 x 10
PRRS
neg. Blood Blood BloodBlood Blood
21 days
BloodBlood Blood
d0 7 14 21 45
4
23835
Blood
49
Daily monitoring clinic, temperature d0 – d49
Strict controls
2 NV --> chall. Diff.
strains (lineage 1 or 5)
2 Vax--> chall. Diff.
strains (lineage 1 or 5)
25. Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against
26. Design Parameters Results Movinggraphs
Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against
27. Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against
28. Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against
29. Patterson 2016
Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge, Patterson et al, Leman 2016
31. Design Parameters Results Movinggraphs
Day 42 Percent Lung Lesions (Median)
asignificantly different from the placebo at P≤0.05
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
32. Design Parameters Results Movinggraphs
Post-challenge ADWG
Group Treatment ADWG in lbs.
1 Ingelvac PRRS® MLV 0.61a
2 Fostera® PRRS 0.49a*
3 Placebo 0.24b
asignificantly different from the placebo at P≤0.05
*different from Ingelvac PRRS® MLV at P≤0.1
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
33. Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
34. Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
35. Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
36. Design Parameters Results Movinggraphs
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,
39. Design Parameters Results Movinggraphs
G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs
40. This study has relevance in the field as
implementation of vaccine in a systematic and
coordinated methodology in a “system-based”
and “area/region-based” program can mitigate
the consequences of PRRSV infection –
subsequently improving health and performance
– and may reduce the level of challenge virus
within and between vaccinated populations
over-time further limiting the consequences of
infection in vaccinated populations
Reid Philips, AASV 2016
Design Parameters Results Movinggraphs
G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs
41. G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs
42. G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs
43. PRRS immunity across the world
Wei, Vaccine 2013
Jeung, Vet, Micr. 2016
Patterson 2016
Muehlenthaler, 2012
Haiwick 2016
44. What’s new on immunological cross-protection
■ Genotype does not predict the level of protection
■ Nothing new!
■ Geography does not predict the level of protection
■ Nothing new!
■ Challenge dose plays an important role in the level of efficacy
■ Reduction of wild type circulation is important
45. Reid Philips Enrique Mondaca Xavier de Paz CarloMaala
RyanHuang OliverDuran JoeVictoria
A.Patterson
G.Haiwick
Thanks to